BLR&D Research Career Scientist Award Application

与肥胖相关的发病率和死亡率是VA患者的主要健康问题 人口有大量证据表明，肥胖会增加患各种癌症的风险。的 VA每年报告约40，000例新发癌症病例，其中约2.7-3%为肝癌。肥胖与 代谢紊乱，如非酒精性脂肪性肝病（NAFLD）及其更严重的形式， 酒精性脂肪变性（NASH），这些都是肝硬化和肝癌的危险因素。所以慢性肝病 无论是由病毒感染、饮酒、肥胖或其任何组合引起的疾病， 导致肝硬化并最终导致肝癌。退伍军人人群是肥胖相关肝脏的高风险人群 因此，了解疾病的病因和发病机制是很重要的。 同样，肥胖人群中乳腺癌的发病率也会增加， 肥胖与乳腺癌的关系在绝经后妇女中尤为明显。八分之一的女性 会被诊断出患有乳腺癌。随着越来越多的女性进入军队 服务，妇女的健康问题成为退伍军人事务部更大的关注。在战场上接触有毒物质， 营养不良可能会引发代谢综合征，这与心脏病、糖尿病 和癌症研究了解环境和营养事件如何影响正常的 代谢将更清楚地揭示代谢失调如何增加各种疾病的风险。 我们发现，减少炎症和胰岛素抵抗可以减少小鼠乳腺癌的生长。 这可以通过提供高水平的ω 3脂肪酸或通过营养干预来实现， 限时喂食高脂肪食物。由于肥胖、胰岛素抵抗和乳腺癌之间的联系 绝经后妇女的风险，以及类似的时间限制，饮食干预可能 预防人类乳腺癌，重要的是要了解如何纠正胰岛素抵抗 降低小鼠乳腺癌生长的风险，并研究可能导致乳腺癌的生理变化。 肥胖中的肿瘤生长。 我们已经发表了肝细胞中一种特定RNA剪接因子SRSF 3的缺失导致慢性 肝损伤、葡萄糖和脂质代谢的破坏、炎症、纤维化和最终的肝癌。 因此，剪接因子的丢失不会导致肿瘤，而是产生了癌症的易感性，类似于 一个肿瘤抑制基因。我们已经证明，SRSF 3的丢失在早期肝病中发现， 除了在肝癌中丢失外，SRSF 3的丢失可能是诱发肝癌的因素， 会引发进行性肝病我们的研究将解决有关基本的关键问题， 蛋白质稳态的生物过程和肝脏中的致癌作用，并将整合生化，细胞 以及在肝脏中缺乏特异性剪接因子的小鼠中进行生理学研究的分子生物学实验。 我们将研究在小鼠中阻止SRSF 3的降解是否足以阻止肿瘤的进展。 早期肝病炎症，纤维化和肝硬化，我们将确定这种方法是否 预防肝癌或可用于逆转小鼠肝癌。 最后，肥胖与组织炎症有关，我们已经证明，改变组织中cAMP水平， 树突状细胞改变其指导T细胞发育成Th 2或Th 17谱系的能力。这具有重要 作为Th 2偏好的代谢后果防止高脂肪饮食诱导的肥胖和胰岛素抵抗。我们 进一步发现，Th 17偏向性炎症的诱导加速了小鼠肺癌的发生， 17 A阻止肿瘤生长。我们的研究旨在了解炎症与 代谢，以及它们如何改变肺癌的生长。这是VA患者的一个重要研究领域 吸烟在退伍军人中很常见。

The morbidity and mortality associated with obesity is a major health problem in the VA patient population. There is abundant evidence that obesity confers increased risk for various forms of cancer. The VA reports ~40,000 new cases of cancer per year and ~2.7-3% are liver cancer. Obesity is associated with metabolic disturbances such as non-alcoholic fatty liver disease (NAFLD) and its more severe form non- alcoholic steatosis (NASH) and these are risk factors for both cirrhosis and liver cancer. So chronic liver disease, whether induced by viral infection, alcohol use, obesity or any combination thereof, is the major risk factor for cirrhosis and ultimately liver cancer. The Veteran population is at high risk for obesity-associated liver disease and hence liver cancer so it is important to understand the etiology and pathogenesis of the disease. Similarly the incidence of breast cancer is increased in obese populations, and the epidemiologic evidence for the obesity-breast cancer connection is particularly strong in post-menopausal women. One in eight women will be diagnosed with breast cancer during their lifetime. As increasing numbers of women enter military service, women’s health issues become a greater concern for the VA. Battlefield exposures to toxicants and bad nutrition may trigger the metabolic syndrome that is associated with higher risk of heart disease, diabetes and cancer. Studies to understand how environmental and nutritional events impact the regulation of normal metabolism will shed greater light on how metabolic dysregulation increases the risk of various diseases. We have found that reducing inflammation and insulin resistance reduces breast cancer growth in mice. This can be done by providing high levels of omega3 fatty acids or through a nutritional intervention involving time-restricted feeding of a high-fat diet. Due to the link between obesity, insulin resistance and breast cancer risk in post-menopausal women, and the potential that a similar time-restricted, dietary intervention could protect against breast cancer in humans, it is important to understand how correcting insulin resistance reduces the risk of breast cancer growth in mice and investigate the physiological changes that may drive tumor growth in obesity. We have published that loss of a particular RNA splicing factor SRSF3 in hepatocytes causes chronic liver damage, disruptions in glucose and lipid metabolism, inflammation, fibrosis, and eventually liver cancer. So the loss of the splicing factor does not cause tumors but rather creates a pre-disposition to cancer, similar to a tumor suppressor gene. We have since shown that loss of SRSF3 is found in early liver disease in both humans and mice, in addition to being lost in liver cancer, so loss of SRSF3 may be the precipitating event that triggers progressive liver disease. Our studies will address key questions concerning the fundamental biological process of protein homeostasis and carcinogenesis in the liver and will integrate biochemical, cell and molecular biological experiments with physiological studies in mice lacking specific splicing factors in liver. We will investigate whether preventing degradation of SRSF3 in mice is sufficient to prevent the progression of early liver disease to inflammation, fibrosis and cirrhosis, and we will determine whether this approach prevents liver cancer or can be used to reverse liver cancer in mice. Lastly, obesity is associated with tissue inflammation and we have shown that altering cAMP levels in dendritic cells changes their ability to instruct T cells to develop into Th2 or Th17 lineages. This has important metabolic consequences as a Th2 bias prevents high-fat diet induced obesity and insulin resistance. We furthermore found that induction of a Th17 biased inflammation accelerates lung cancer in mice, and loss of IL- 17A prevents tumor growth. Our studies are designed to understand the link between inflammation and metabolism, and how these alter lung cancer growth. This is an important area of research for the VA patient population as smoking is common among veterans.